Boston Scientific To Study Complex DES Use; Taxus Complaints Surface
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is maintaining a "sober" outlook regarding its chances of obtaining increased reimbursement in the near-term for multi-vessel interventions using drug-eluting stents
You may also be interested in...
Can DES Improve Diabetic Outcomes? Cardiologists Turn FREEDOM Fighters
Drug-eluting stent trial and registry data suggest the technology is catching up with bypass surgery in reducing repeat revascularizations in diabetics, but researchers await clarity on the most elusive endpoint of all - survival
Can DES Improve Diabetic Outcomes? Cardiologists Turn FREEDOM Fighters
Drug-eluting stent trial and registry data suggest the technology is catching up with bypass surgery in reducing repeat revascularizations in diabetics, but researchers await clarity on the most elusive endpoint of all - survival
Guidant, Boston Scientific Stocks Weather DES Issues
Guidant's July 1 confirmation that design changes to its Champion everolimus drug-eluting stent will only delay a launch by six to eight months appears to have partially allayed investor concerns after an initial stock sell-off in May